Primary Tumor Resection for Stage IV Non-small-cell Lung Cancer Without Progression After First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment: A Retrospective Case-Control Study

SHUENN-WEN KUOPEI-HSING CHENTZU-PIN LUKE-CHENG CHENHSIEN-CHI LIAOTsou, Kuan-ChuanKuan-ChuanTsouTUNG-MING TSAIMONG-WEI LINHSAO-HSUN HSUJIN-SHING CHEN2022-07-212022-07-212022-081068-9265https://scholars.lib.ntu.edu.tw/handle/123456789/615800In studies of stage IV epidermal growth factor receptor (EGFR)-mutant nonsmall-cell lung cancer (NSCLC), <10% of patients underwent surgery; thus, the effect of surgery in these patients remains unclear. We investigated whether primary lung tumor resection could improve the survival of patients with stage IV EGFR-mutant NSCLC without progression after first-line EGFR-tyrosine kinase inhibitor (EGFR-TKI) treatment.enOPEN-LABEL; MAINTENANCE THERAPY; ABLATIVE THERAPY; SYSTEMIC THERAPY; EGFR MUTATIONS; ASIAN PATIENTS; ERLOTINIB; CHEMOTHERAPY; MULTICENTER; ADENOCARCINOMA[SDGs]SDG3Primary Tumor Resection for Stage IV Non-small-cell Lung Cancer Without Progression After First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Treatment: A Retrospective Case-Control Studyjournal article10.1245/s10434-022-11483-7352545832-s2.0-85125706924WOS:000765730700007https://scholars.lib.ntu.edu.tw/handle/123456789/597356